Classifying Polypharmacy According to Pharmacotherapeutic and Clinical Risks in Older Adults: A Latent Class Analysis in Quebec, Canada.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
29
03
2023
medline:
2
6
2023
pubmed:
7
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
The simplistic definition of polypharmacy, often designated as the concomitant use of five medications or more, does not distinguish appropriate from inappropriate polypharmacy. Classifying polypharmacy according to varying levels of health risk would help optimise medication use. We aimed to characterise different types of polypharmacy among older adults and evaluate their association with mortality and institutionalisation. Using healthcare databases from the Quebec Integrated Chronic Disease Surveillance System, we selected a community-based random sample of the population ≥ 66 years old covered by the public drug plan. Categorical indicators used to describe polypharmacy included number of medications, potentially inappropriate medications (PIMs), drug-drug interactions, enhanced surveillance medications, complex route of administration medications, anticholinergic cognitive burden (ACB) score and use of blister cards. We used a latent class analysis to subdivide participants into distinct groups of polypharmacy. Their association with 3-year mortality and institutionalisation was assessed with adjusted Cox models. In total, 93,516 individuals were included. A four-class model was selected with groups described as (1) no polypharmacy (46% of our sample), (2) high-medium number of medications, low risk (33%), (3) medium number of medications, PIM use with or without high ACB score (8%) and (4) hyperpolypharmacy, complex use, high risk (13%). Using the class without polypharmacy as the reference, all polypharmacy classes were associated with 3-year mortality and institutionalisation, with the most complex/inappropriate classes denoting the highest risk (hazard ratio [HR] [95% confidence interval]: class 3, 70-year-old point estimate for mortality 1.52 [1.30-1.78] and institutionalisation 1.86 [1.52-2.29]; class 4, 70-year-old point estimate for mortality 2.74 [2.44-3.08] and institutionalisation 3.11 [2.60-3.70]). We distinguished three types of polypharmacy with varying pharmacotherapeutic and clinical appropriateness. Our results highlight the value of looking beyond the number of medications to assess polypharmacy.
Identifiants
pubmed: 37149556
doi: 10.1007/s40266-023-01028-2
pii: 10.1007/s40266-023-01028-2
doi:
Substances chimiques
Cholinergic Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-583Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Lancet T. Making more of multimorbidity: an emerging priority. Lancet. 2018;391:1637. https://doi.org/10.1016/S0140-6736(18)30941-3 .
doi: 10.1016/S0140-6736(18)30941-3
Gosselin E, Simard M, Dubé M, Sirois C. Portrait de la polypharmacie chez les aînés québécois entre 2000 et 2016. Gouvernement du Québec: Institut national de santé publique du Québec; 2020.
Sirois C, Domingues NS, Laroche ML, et al. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy. 2019;7(3):126. https://doi.org/10.3390/pharmacy7030126 .
doi: 10.3390/pharmacy7030126
pubmed: 31470621
pmcid: 6789889
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. https://doi.org/10.1517/14740338.2013.827660 .
doi: 10.1517/14740338.2013.827660
pubmed: 24073682
Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8(5): e019101. https://doi.org/10.1136/bmjopen-2017-019101 .
doi: 10.1136/bmjopen-2017-019101
pubmed: 29730617
pmcid: 5942474
Li Y, Zhang X, Yang L, et al. Association between polypharmacy and mortality in the older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2022;100: 104630. https://doi.org/10.1016/j.archger.2022.104630 .
doi: 10.1016/j.archger.2022.104630
pubmed: 35101709
Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9. https://doi.org/10.2147/CIA.S2468 .
doi: 10.2147/CIA.S2468
pubmed: 18686760
pmcid: 2546482
Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021;77(2):147–62. https://doi.org/10.1007/s00228-020-02994-x .
doi: 10.1007/s00228-020-0299x
pubmed: 33011824
Masnoon N, Kalisch Ellett L, Shakib S, Caughey GE. Predictors of mortality in the older population: the role of polypharmacy and other medication and chronic disease-related factors. Drugs Aging. 2020;37(10):767–76. https://doi.org/10.1007/s40266-020-00794-7 .
doi: 10.1007/s40266-020-00794-7
pubmed: 32885396
Roux B, Sirois C, Simard M, Gagnon M-E, Laroche M-L. Potentially inappropriate medications in older adults: a population-based cohort study. Fam Pract. 2019;37(2):173–9. https://doi.org/10.1093/fampra/cmz060 .
doi: 10.1093/fampra/cmz060
Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health outcomes in ageing populations: a systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85(11):2464–78. https://doi.org/10.1111/bcp.14075 .
doi: 10.1111/bcp.14075
pubmed: 31486099
pmcid: 6848955
Carr E, Federman A, Dzahini O, Dobson RJ, Bendayan R. A multidimensional measure of polypharmacy for older adults using the Health and Retirement Study. Sci Rep. 2021;11(1):8783. https://doi.org/10.1038/s41598-021-86331-x .
doi: 10.1038/s41598-021-86331-x
pubmed: 33888728
pmcid: 8062687
Akpan A, Roberts C, Bandeen-Roche K, et al. Standard set of health outcome measures for older persons. BMC Geriatr. 2018;18(1):36. https://doi.org/10.1186/s12877-017-0701-3 .
doi: 10.1186/s12877-017-0701-3
pubmed: 29394887
pmcid: 5797357
Blais C, Jean S, Sirois C, et al. Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach. Chronic Dis Inj Can. 2014;34(4):226–35.
doi: 10.24095/hpcdp.34.4.06
pubmed: 25408182
Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995;48(8):999–1009. https://doi.org/10.1016/0895-4356(94)00234-H .
doi: 10.1016/0895-4356(94)00234-H
pubmed: 7775999
Collins LM, Lanza ST. Latent class and latent transition analysis with applications in the social, behavioral, and health sciences. Pennsylvania: Wiley; 2010. p. 3–5.
Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94. https://doi.org/10.1080/10705510701575602 .
doi: 10.1080/10705510701575602
Nylund-Gibson K, Choi AY. Ten frequently asked questions about latent class analysis. Transl Issues Psychol Sci. 2018;4(4):440. https://doi.org/10.1037/met0000486 .
doi: 10.1037/met0000486
Bakoyannis G, Touloumi G. Practical methods for competing risks data: a review. Stat Methods Med Res. 2012;21(3):257–72. https://doi.org/10.1177/0962280210394479 .
doi: 10.1177/0962280210394479
pubmed: 21216803
American Geriatrics Society Beers Criteria
IBM Micromedex. Drug interactions. IBM Corporation. 2022. https://www.micromedexsolutions.com/home/dispatch . Accessed Dec 2021.
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.
doi: 10.2217/1745509X.4.3.311
Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada). 2010;8(1):50–5. https://doi.org/10.4321/s1886-36552010000100006 .
doi: 10.4321/s1886-36552010000100006
pubmed: 25152793
pmcid: 4140577
Institute for Safe Medication Practices. High-Alert Medications in Community/Ambulatory Care Settings. 2021. https://www.ismp.org/recommendations/high-alert-medications-community-ambulatory-list . Accessed Dec 2021.
Simard M, Sirois C, Candas B. Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD-9 and ICD-10. Med Care. 2018;56(5):441–7. https://doi.org/10.1097/MLR.0000000000000905 .
doi: 10.1097/MLR.0000000000000905
pubmed: 29578951
Spiegl K, Luttenberger K, Graessel E, Becker L, Scheel J, Pendergrass A. Predictors of institutionalization in users of day care facilities with mild cognitive impairment to moderate dementia. BMC Health Serv Res. 2021;21(1):1009. https://doi.org/10.1186/s12913-021-07017-8 .
doi: 10.1186/s12913-021-07017-8
pubmed: 34556085
pmcid: 8461860
Wolff J, Reißner P, Hefner G, et al. Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. PLoS ONE. 2021;16(7): e0255192. https://doi.org/10.1371/journal.pone.0255192 .
doi: 10.1371/journal.pone.0255192
pubmed: 34293068
pmcid: 8297778
George J, Phun Y-T, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369–76. https://doi.org/10.1345/aph.1D479 .
doi: 10.1345/aph.1D479
pubmed: 15266038
Cross AJ, George J, Woodward MC, et al. Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia. Drugs Aging. 2016;33(1):37–44. https://doi.org/10.1007/s40266-015-0332-3 .
doi: 10.1007/s40266-015-0332-3
pubmed: 26645294
Jang S, Jeong S, Jang S. Patient- and prescriber-related factors associated with potentially inappropriate medications and drug-drug interactions in older adults. J Clin Med. 2021;10(11):2305. https://doi.org/10.3390/jcm10112305 .
doi: 10.3390/jcm10112305
pubmed: 34070618
pmcid: 8198936
Al-Azayzih A, Alamoori R, Altawalbeh SM. Potentially inappropriate medications prescribing according to Beers criteria among elderly outpatients in Jordan: a cross sectional study. Pharm Pract (Granada). 2019;17(2):1439. https://doi.org/10.18549/PharmPract.2019.2.1439 .
doi: 10.18549/PharmPract.2019.2.1439
pubmed: 31275497
pmcid: 6594439
Squires P, Pahor M, Manini TM, Vouri S, Brown JD. Impact of anticholinergic medication burden on mobility and falls in the Lifestyle Interventions for Elders (LIFE) study. J Clin Med. 2020;9(9):2989. https://doi.org/10.3390/jcm9092989 .
doi: 10.3390/jcm9092989
pubmed: 32947839
pmcid: 7564216
Lockery JE, Broder JC, Ryan J, et al. A cohort study of anticholinergic medication burden and incident dementia and stroke in older adults. J Gen Intern Med. 2021;36(6):1629–37. https://doi.org/10.1007/s11606-020-06550-2 .
doi: 10.1007/s11606-020-06550-2
pubmed: 33754317
pmcid: 8175463
Campbell NL, Perkins AJ, Bradt P, et al. Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population. Pharmacotherapy. 2016;36(11):1123–31. https://doi.org/10.1002/phar.1843 .
doi: 10.1002/phar.1843
pubmed: 27711982
pmcid: 5362375
de Araújo NC, Silveira EA, Mota BG, et al. Potentially inappropriate medications for the elderly: Incidence and impact on mortality in a cohort ten-year follow-up. PLoS ONE. 2020;15(10): e0240104. https://doi.org/10.1371/journal.pone.0240104 .
doi: 10.1371/journal.pone.0240104
pubmed: 33112864
pmcid: 7592782
Huang CH, Umegaki H, Watanabe Y, et al. Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. PLoS ONE. 2019;14(2): e0211947. https://doi.org/10.1371/journal.pone.0211947 .
doi: 10.1371/journal.pone.0211947
pubmed: 30735544
pmcid: 6368320
Parekh N, Ali K, Davies JG, Rajkumar C. Do the 2015 Beers Criteria predict medication-related harm in older adults? Analysis from a multicentre prospective study in the United Kingdom. Pharmacoepidemiol Drug Saf. 2019;28(11):1464–9. https://doi.org/10.1002/pds.4849 .
doi: 10.1002/pds.4849
pubmed: 31338909
Xing XX, Zhu C, Liang HY, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. Ann Pharmacother. 2019;53(10):1005–19. https://doi.org/10.1177/1060028019853069 .
doi: 10.1177/1060028019853069
pubmed: 31129978
Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schöttker B. The association of potentially inappropriate medication at older age with cardiovascular events and overall mortality: a systematic review and meta-analysis of cohort studies. J Am Med Dir Assoc. 2017;18(3):211–20. https://doi.org/10.1016/j.jamda.2016.11.025 .
doi: 10.1016/j.jamda.2016.11.025
pubmed: 28131719
Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–15. https://doi.org/10.1093/ageing/afu096 .
doi: 10.1093/ageing/afu096
pubmed: 25038833
Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76(3):319–35. https://doi.org/10.1007/s00228-019-02795-x .
doi: 10.1007/s00228-019-02795-x
pubmed: 31832732
Salminen M, Laine J, Vahlberg T, et al. Factors associated with institutionalization among home-dwelling patients of Urgent Geriatric Outpatient Clinic: a 3-year follow-up study. Eur Geriatr Med. 2020;11(5):745–51. https://doi.org/10.1007/s41999-020-00338-7 .
doi: 10.1007/s41999-020-00338-7
pubmed: 32500517
pmcid: 7550301
Wauters M, Elseviers M, Vaes B, et al. Mortality, hospitalisation, institutionalisation in community-dwelling oldest old: the impact of medication. Arch Gerontol Geriatr. 2016;65:9–16. https://doi.org/10.1016/j.archger.2016.02.009 .
doi: 10.1016/j.archger.2016.02.009
pubmed: 26913791
Rosenberg T, Montgomery P, Hay V, Lattimer R. Using frailty and quality of life measures in clinical care of the elderly in Canada to predict death, nursing home transfer and hospitalisation - the frailty and ageing cohort study. BMJ Open. 2019;9(11): e032712. https://doi.org/10.1136/bmjopen-2019-032712 .
doi: 10.1136/bmjopen-2019-032712
pubmed: 31722953
pmcid: 6858169
De Buyser SL, Petrovic M, Taes YE, Vetrano DL, Onder G. A multicomponent approach to identify predictors of hospital outcomes in older in-patients: a multicentre, observational study. PLoS ONE. 2014;9(12):e115413-e. https://doi.org/10.1371/journal.pone.0115413 .
doi: 10.1371/journal.pone.0115413
Joling KJ, Janssen O, Francke AL, et al. Time from diagnosis to institutionalization and death in people with dementia. Alzheimers Dement. 2020;16(4):662–71. https://doi.org/10.1002/alz.12063 .
doi: 10.1002/alz.12063
pubmed: 32072728
pmcid: 7984226
Luppa M, Luck T, Weyerer S, König H-H, Brähler E, Riedel-Heller SG. Prediction of institutionalization in the elderly. A systematic review. Age Ageing. 2009;39(1):31–8. https://doi.org/10.1093/ageing/afp202 .
doi: 10.1093/ageing/afp202
pubmed: 19934075
Taylor-Rowan M, Edwards S, Noel-Storr AH, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5(5):CD013540. https://doi.org/10.1002/14651858.CD013540.pub2 .
Manias E, Kabir MZ, Maier AB. Inappropriate medications and physical function: a systematic review. Ther Adv Drug Saf. 2021;12:20420986211030372. https://doi.org/10.1177/2042098621103037 .
doi: 10.1177/2042098621103037
pubmed: 34349978
pmcid: 8287273
Franchi C, Marcucci M, Mannucci PM, et al. Changes in clinical outcomes for community-dwelling older people exposed to incident chronic polypharmacy: a comparison between 2001 and 2009. Pharmacoepidemiol Drug Saf. 2016;25(2):204–11. https://doi.org/10.1002/pds.3938 .
doi: 10.1002/pds.3938
pubmed: 26687829